update in infectious diseases 2012 keith b. armitage, md professor of medicine case western reserve...
TRANSCRIPT
![Page 1: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/1.jpg)
Update in Infectious Diseases 2012
Keith B. Armitage, MDProfessor of Medicine
Case Western Reserve University
![Page 2: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/2.jpg)
Disclosures
• No conflicts
![Page 3: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/3.jpg)
Topics
• Clostridium difficile infection (CDI)• Update on antimicrobial agents• Miscellaneous updates
![Page 4: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/4.jpg)
Clostridium difficile infection
• CDI > MRSA for nosocomial infection– Long term care facilities
• “Epidemic strain”– NEJM 12/05; NAP1 strain– Increase in frequency and severity• 10x increase in reports of CDI as primary cause of death
1999-2009
• Change in antimicrobial risk– Quinolones >> cephalosporins > clindamycin
![Page 5: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/5.jpg)
Clostridium difficile
• New testing method– PCR 85 % to 95 % sensitive; quick turnaround time– Prior toxin assays- 28 % sensitive!
• Relapses- 20 %- predicted by age, severity of presentation, hospital exposure, prior CDI relapse
• New therapies– Fidaxomicin– Stool transplants
![Page 6: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/6.jpg)
Audience Response Question
• For hospitalized patients with suspected or proven mild to moderate CD- I most often start with :– 1. oral metronidazole– 2. oral vancomycin– 3. IV metronidazole– 4. oral vanco + IV metronidazole– 5. fidaxomicin
![Page 7: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/7.jpg)
Clostridium difficile- treatment options
• Oral or IV metronidazole– Mild to moderate– Inferior to vancomycin for severe CDI
• Oral vancomycin– 125 mg dose adequate– Impact on the gastrointestinal microbiome– Cost- more and more pharmacies are
compounding• vs. Fidaxomicin
![Page 8: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/8.jpg)
Clostridium difficile
• Fidaxomicin– First in class macrocyclic antibiotic– Theoretical advantages
• More active against NAP1 strain• Inhibits spore and toxin production• Less impact on the normal flora
– Decrease VRE colonization
• High fecal concentration with minimal systemic absorption
– Cost• $ 2800 for a 10 day course
![Page 9: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/9.jpg)
Fidaxomicin
• Initial two licensing studies- non inferior to vancomycin with fewer relapses in the non-NAP1 strain
• Meta-analysis – superior for recurrence and global cure, including NAP1, but no difference in an intention to treat analysis– Subgroup analysis suggests benefit
![Page 10: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/10.jpg)
Fidaxomicin
• Recent multicenter trial in 1164 patients with first recurrence- vancomycin vs. fidaxomicin– Same response to therapy– Superior in preventing second relapse
• ? More data needed to justify cost?
![Page 11: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/11.jpg)
Clostridium difficile-multiple relapses
• Long tapering courses• Fidaxomicin ?• Probiotics– Not helpful in patients with relapses
• Stool transplants– Strong results in case series• Sonication, filter, instill via nasogastric tube
– No comparator trials
![Page 12: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/12.jpg)
Clostridium difficile- treatment options
• Nitazoxanide• Rifaximin– Used as chaser in multiple recurrences- small
study
• Tigecycline– Dose not promote CD growth despite broad
spectrum– Very limited data in CDI
![Page 13: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/13.jpg)
Clostridium difficile
• CDI and PPIs– 2012 FDA warning– 1.4 to 2.75x risk in patients on PPIs– Relationship of dose and duration unknown– FDA recommends lowest dose for lowest duration
in patients at risk for CDI
![Page 14: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/14.jpg)
Update on antimicrobial agents
• New antimicrobial agents for gram positive infections in the past fifteen years– Daptomycin– Linezolid– Synercid – Ceftaroline– Telavancin– Tigecycline
![Page 15: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/15.jpg)
Update on antimicrobial agents
• New antimicrobial agents for gram negative infections in the past decade, or in the pipeline………. Tigecycline ? otherwise
![Page 16: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/16.jpg)
Audience Response Question
• For outpatients with suspected Staphylococcus aureus skin and soft tissue infections, I most prescribe:– 1. Augmentin– 2. Bactrim– 3. Clindamycin– 4. Doxycycline– 5. Linezolid– 6. One of the above plus Keflex
![Page 17: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/17.jpg)
New antimicrobial agents for gram positive infections
• Linezolid– Not new, but……– Best oral bioavailability– SSRIs– Cytopenias– Cost
![Page 18: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/18.jpg)
New antimicrobial agents for gram positive infections
• Daptomycin– IV only– Not in the lung– Once a day• Weekly CPK
– Tends to not be particularly helpful in the VISA strains
![Page 19: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/19.jpg)
Vancomycin dosing/levels
• New dosing recommendations• Vancomycin levels– Serious infections; increased MICs- trough 15-20– ‘minor infections’- 5-10– Dosing apps
![Page 20: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/20.jpg)
Ceftaroline
• Novel cephalosporin that has activity against MRSA– Maintains the broad spectrum gram negative
activity of advanced generation cephalosporins
• Skin and soft tissue, community acquired pneumonia
![Page 21: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/21.jpg)
Tigecycline
• Tetracycline antibiotic• Broad spectrum, including MRSA– Does not cover “P P P”• Pseudomonas, Proteus, Providencia
• Used primarily in patients intolerant to other antibiotics; multiple allergies
• 2012 meta-analysis- small increase in mortality
• Tolerance
![Page 22: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/22.jpg)
Telavancin
• semi-synthetic derivative of vancomycin• Once a day• Meta-Analysis- Telavancin vs. vancomycin– Non inferior vs. vancomycin– Associated with higher eradication rates and trend
towards better clinical response– All cause mortality equivalent– High rate of adverse events, including elevations
in serum creatinine
![Page 23: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/23.jpg)
Brief Updates-2012 FDA advisories
• Cefepime/seizures- Too high doses in patients with renal impairment
• Azithromycin/cardiovascular risk– Class effect on QT; torsades de pointes– Large database- increased cardiovascular death vs.
amoxicillin • Similar to quinolones• Highest in patients with cardiovascular risk factors
• Quinolones/retinal detachment– Possible increased risk
![Page 24: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/24.jpg)
Vaccines
• HSV vaccine trial- no efficacy• Zoster vaccination– New age recommendation
• ACIP > 60 (FDA > 50)– Currently contraindicated in high level
immunosuppression– Safe in low levels of Imuran, mtx, steroids– > 20 mg prednisone for 3 weeks– Large database analysis of patient with Crohn’s and RA
showed no risk of adverse reactions– Larger trials needed for confirmation
![Page 25: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/25.jpg)
Vaccines• Pertussis vaccination in adults
– 2012 ACIM recommends T-dap booster for all adults- regardless of age
• Pneumococcal conjugate vaccine in healthy adults– 13-valent conjugate vaccine approved December 2011 in adults
> 50– Antibody responses =/> than pneumococcal polysaccharide
vaccine– Recommended by ACIP for routine use in adults- pending
additional data – June 2012- ACIP recommended use in immunocompromised
adults age > 19• May give in addition to polysaccharide vaccine- one or more year later• Evolving recommendations- recommend ACIP web site or app
![Page 26: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/26.jpg)
Vaccines
• Influenza 2012-2013– 2010: all persons > 6
– A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Wisconsin/1/2010
– Vaccinate as soon as vaccine available……– Fluzone high dose- indicated for persons age > 65
– 4x antigen– Shown to invoke stronger immune response, but protective efficacy
not clear; studies ongoing– Do not use in patients with prior vaccine reaction
– Egg allergy- hives only• 30 minutes observation• trivalent inactivated vaccine only
![Page 27: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/27.jpg)
Mycobacterium
• New recommendation for latent TB– Rifapentine- longer half life and greater potency
than rifampin– Three month course of weekly directly observed
therapy of rifapentine/INH non-inferior to nine months of INH
– CDC recommends rifapentine/INH as alternative to nine months of INH in patients > 12 months • Advantage of DOT
![Page 28: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/28.jpg)
Chronic Fatigue Syndrome- 2012
• Retraction of two studies that initially associated CFS with retrovirus infection
![Page 29: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/29.jpg)
HIV• Rapid in-home testing approved but not yet
commercially available• 2012 US Department of Health and Human Services
recommended therapy for HIV infected patients regardless of CD4 count
• Pre-exposure prophylaxis:• July 2012 FDA approved tenofovir-emtricitabine
(truvada) among confirmed HIV negative individuals at high risk for sexually acquired HIV– Counseling about factors– Evaluation for HIV prior to initiation crucial to avoid
selection of mutations
![Page 30: Update in Infectious Diseases 2012 Keith B. Armitage, MD Professor of Medicine Case Western Reserve University](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56649e9f5503460f94ba2209/html5/thumbnails/30.jpg)
H3N2 Variant Influenza
• CDC reports > 150 cases of H3N2 variant influenza caused by reassortment of swine H3N2 and H1N1; most cases have occurred since July 2012– All patients reported contact with swine
(including fairs)– Mild diseases- two hospitalizations; no deaths– CDC recommends frequent hand washing and
avoiding contact with pigs that appear ill